^
    Back
    Association details:
    Biomarker:CYP1A1 I462V
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Pharmacol
    Title:

    Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients

    Published date:
    05/08/2020
    Excerpt:
    Erlotinib steady state trough concentration was remarkably lower in current smoking patients. The steady state trough concentration of GG in rs1048943 of CYP1A1 was significantly higher than that of AA allele carriers…We also observed that GG allele in CYP1A1 was accompanied with a longer PFS in our study.
    DOI:
    10.3389/fphar.2020.00664